Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced ...

A proposal to allow Medicare coverage of anti-obesity drugs such as Wegovy and Zepbound has been officially dropped by the Centers for Medicare and Medicaid Services (CMS), dealing a setback to ...

Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and Wegovy. The rule was not expected to be ...

About Veru Inc. Veru is a late clinical stage biopharmaceutical ... patients receiving semaglutide (Wegovy®). The trial met its prespecified primary endpoint with a statistically significant ...

About Veru Inc. Veru is a late clinical stage biopharmaceutical ... patients receiving semaglutide (Wegovy ®). The trial met its prespecified primary endpoint with a statistically significant and a ...

MIAMI, FL, March 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...